Group 1 - The Fidelity Nasdaq Composite Index ETF (NASDAQ:ONEQ) is down 10% year-to-date through late March 2026, with its heaviest positions contributing to this decline [1] - ONEQ aims to provide a low-cost way to invest in the entire Nasdaq Composite, holding 1,031 securities, including mid-cap and smaller companies, with an expense ratio of 0.21% and assets totaling $8.77 billion [2] - The fund is highly sensitive to interest rates, with 47% of its holdings in Information Technology and 17% in Communication Services, making it one of the most rate-sensitive broad index ETFs [3] Group 2 - The current 10-Year Treasury yield is at 4.42%, having increased nearly 0.4% over the past month, which affects the present value of future earnings for growth stocks [4] - If the 10-year yield approaches 4.6%, it may exert renewed pressure on the fund's major tech holdings, while any pivot by the Federal Reserve towards rate cuts could provide relief [5] - ONEQ has a significant concentration risk, with nearly 11% of the fund invested in Nvidia and another 11% in Apple, together representing over 20% of the fund [6]

Core Viewpoint - Analysts project an 11.22% upside for the Fidelity Nasdaq Composite Index ETF (ONEQ) based on its underlying holdings, with an implied target price of $97.48 per unit compared to its recent trading price of $87.65 [1][2]. Summary by Category ETF Overview - The Fidelity Nasdaq Composite Index ETF (ONEQ) is currently trading at $87.65, with an implied analyst target price of $97.48, indicating a potential upside of 11.22% [1][2][3]. Underlying Holdings - Structure Therapeutics Inc (GPCR) has a recent price of $21.65, with an average analyst target of $76.00, representing a significant upside of 251.04% [2][3]. - Grupo Financiero Galicia SA (GGAL) is trading at $29.56, with an average target price of $63.33, indicating a potential upside of 114.25% [2][3]. - Criteo S.A. (CRTO) has a recent price of $22.44, with an average target price of $38.55, suggesting an upside of 71.81% [2][3]. Analyst Target Justification - Questions arise regarding whether analysts' targets are justified or overly optimistic, considering recent company and industry developments [3].